Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Thijssen

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|July 20, 2024
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implicationsMing-Yuan Gao, Angela Georgiou, Victor S Lin, et al.
Blood Advances|December 3, 2021
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitorsElla R Thompson, Tamia Nguyen, Yamuna Kankanige, et al.
Genome Research|January 10, 2025
Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genesHongke Peng, Jafar S Jabbari, Luyi Tian, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Blood|January 18, 2020
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxPiers Blombery, Ella R Thompson, Tamia Nguyen, et al.
Blood|September 10, 2013
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cellsMaria Fernanda Pascutti, Margot Jak, Jacqueline M Tromp, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Cancer Discovery|December 6, 2018
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaPiers Blombery, Mary Ann Anderson, Jia-Nan Gong, et al.
Blood|May 29, 2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaRachel Thijssen, Johanna Ter Burg, Brett Garrick, et al.
Blood|June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapyRachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|July 20, 2024
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implicationsMing-Yuan Gao, Angela Georgiou, Victor S Lin, et al.
Blood Advances|December 3, 2021
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitorsElla R Thompson, Tamia Nguyen, Yamuna Kankanige, et al.
Genome Research|January 10, 2025
Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genesHongke Peng, Jafar S Jabbari, Luyi Tian, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Blood|January 18, 2020
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclaxPiers Blombery, Ella R Thompson, Tamia Nguyen, et al.
Blood|September 10, 2013
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cellsMaria Fernanda Pascutti, Margot Jak, Jacqueline M Tromp, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Cancer Discovery|December 6, 2018
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaPiers Blombery, Mary Ann Anderson, Jia-Nan Gong, et al.
Blood|May 29, 2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaRachel Thijssen, Johanna Ter Burg, Brett Garrick, et al.
Blood|June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapyRachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Pageof 3